Type 2 Diabetes Remission in the GLP-1 Era | Prof Roy Taylor

Type 2 Diabetes is a reversible condition driven by chronic calorie excess that causes ectopic fat accumulation in the liver and pancreas, ultimately suppressing insulin-producing beta cells. Prof Roy Taylor’s Twin Cycle model explains that this metabolic dysfunction can be corrected through significant weight loss—typically around 15 kilograms—which clears liver fat and allows beta cells to regain normal function. Long-term data from the DiRECT trial confirms that such interventions achieve durable remission, significantly reducing hospitalizations and cancer risk. While muscle insulin resistance plays a secondary, permissive role, the liver remains the primary driver of disease progression. Emerging pharmacotherapies like GLP-1 agonists assist in weight reduction, yet their long-term success relies on sustainable lifestyle changes and addressing the broader food environment that promotes overconsumption. Remission remains possible even after years of diagnosis, provided the beta cells retain the capacity to recover.